Results for tag: "Glucagon Like Peptide 1 Agonist"

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications. The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more